Alignment Healthcare arrived at its second-quarter report having crossed a quiet threshold most of its history had kept out of reach: a full quarter of clearly profitable Medicare Advantage operations. Revenue climbed 31.6% to $1.34 billion, GAAP net income more than doubled to $36.6 million (net income attributable to the company rose 134%), diluted earnings came in at $0.17 versus $0.07 a year ago, and membership grew 31.5% to approximately 294,100. Management said the quarter beat the high end of guidance across every key metric and raised the midpoint of all full-year guidance - membership, revenue, adjusted gross profit, and adjusted EBITDA. By the standalone numbers, this read like a momentum story accelerating into profitability.
The stock read it differently. After a roughly 90% run from the low-teens in early June to a 52-week high near $25 in early July, the shares have since given the move almost entirely back, trading near $13.40 as of this report - a decline of roughly 46% from the July peak and just above the 52-week low. Two forces sit behind the repricing, and they matter more than the quarter. The first is an accounting-integrity overhang: a former executive officer filed a whistleblower suit on July 7 alleging retaliation after reporting, in the company's words, "accounting irregularities," and the company's California plan is one of those caught up in CMS's expanding risk-adjustment (RADV) audit program - the precise layer of revenue that a Medicare Advantage growth story rests on. The second is the unwind of a heavily shorted stock. Short interest has run near 12% of shares outstanding. The quarter's numbers were strong; the market is pricing a bet against the quality and durability of the risk-adjusted premium revenue that produced them.